The Road More or Less Traveled- Examining the Role of Consolidative Allogeneic Hematopoietic Stem Cell Transplantation After Chimeric Antigen Receptor T Cell Therapy in B-cell ALL
Authors:
- 23 August 2024
- journal article
- research article
- Published by Elsevier in Seminars in Hematology
- Vol. 61 (5) , 314-320
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Should CD19 CAR-T Cells for ALL be Followed by Allogeneic Stem Cell Transplant?Transplantation and Cellular Therapy, 2022
- The role of allogeneic haematopoietic cell transplantation as consolidation after anti-CD19 CAR-T cell therapy in adults with relapsed/refractory acute lymphoblastic leukaemia: a prospective cohort studyBone Marrow Transplantation, 2022
- Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2022
- Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Leukemia Remission Confers a Leukemia-Free Survival AdvantageTransplantation and Cellular Therapy, 2022
- Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with TisagenlecleucelTransplantation and Cellular Therapy, 2021
- Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemiaLeukemia, 2021
- Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysisThe Lancet Haematology, 2020
- Anti‐CD19 chimeric antigen receptor‐modified T‐cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B‐cell acute lymphoblastic leukemia: An open‐label pragmatic clinical trialAmerican Journal of Hematology, 2019
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2015
- Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALLLeukemia, 2002